Oral candidiasis of HIV-infected children undergoing sequential HIV therapies

Medical Mycology

Volumn 47, Issue 2, 2009, Pages 149-156

  Melo, Nadja R ^a,b   Taguchi, Hideaki ^c   Culhari, Vitoria P ^a   Kamei, Katsuhiko ^c   Mikami, Yuzuru ^c   Smith, Stephen N ^d   Vilela, Marluce S ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c CHIBA UNIVERSITY   (Japan)

^d ASTON UNIVERSITY   (United Kingdom)

Author keywords

Candida; HIV; Pediatric

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE;

ADOLESCENT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA HUMICULA; CANDIDA NORVEGENSIS; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDIASIS; CHEILITIS; CHILD; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; DRUG DOSE SEQUENCE; ERYTHEMATOUS CANDIDIASIS; ERYTHEMATOUS GINGIVITIS; FEMALE; FUNGUS ISOLATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; THRUSH; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AZOLES; BRAZIL; CANDIDA; CANDIDIASIS, ORAL; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY;

CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS;

EID: 59249099106     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802195315     Document Type: Article

References (43)

1. Krcmery, V. and Barnes, AJ. (2002) Non-albicans Candida spp. causing fungaemia: Pathogenicity and antifungal resistance. J Hosp Infect, 50, pp. 243-260.
2. Benjamin Jr, DK, Poole, C., Steinbach, WJ, Rowen, JL and Walsh, TJ. (2003) Neonatal candidemia and end-organ damage: A critical appraisal of the literature using meta-analytic techniques. Pediatrics, 112, pp. 634-640.
3. Bodey, GP, Mardani, M. Hanna, HA et al. (2002) The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med, 112, pp. 380-385.
4. Ashman, RB and Papadimitriou, JM. (1995) Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev, 59, pp. 646-672.
5. Mencacci, A., Spaccapelo, R. Del Sero, G et al. (1996) CD4+ T-helper-cell responses in mice with low-level Candida albicans infection. Infect Immun, 64:12, pp. 4907-4914.
6. Hazen, KC. (1995) New and emerging yeast pathogens. Clin Microbiol Rev, 8, pp. 462-478.
7. Sullivan, DJ, Henman, MC Moran, GP et al. (1996) Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species. J Med Microbiol, 44, pp. 399-408.
8. Pfaller, MA, Jones, RN, Messer, SA, Edmond, MB and Wenzel, RP. (1998) National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis, 30, pp. 121-129.
9. Melo, NR, Taguchi, H. Jorge, J. et al. (2004) Oral Candida flora from Brazilian human immunodeficiency virus-infected patients in the highly active antiretroviral therapy era. Mem Inst Oswaldo Cruz, 99, pp. 425-431.
10. Cartledge, JD, Midgley, J. and Gazzard, BG. (1999) Non-albicans oral candidosis in HIV-positive patients. J Antimicrob Chemother, 43, pp. 419-422.
11. Barchiesi, F., Morbiducci, V., Ancarani, F. and Scalise, G. (1993) Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol, 9, pp. 455-456.
12. Nguyen Jr, MH PJ, Morris, AJ Tanner, DC et al. (1996) The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance. Am J Med, 100, pp. 617-623.
13. Sobel, JD, Ohmit, SE Schuman, P. et al. (2001) The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis, 183, pp. 286-293.
14. Dronda, F., Alonso-Sanz, M. Laguna, F. et al. (1996) Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis, 15, pp. 446-452.
15. Hoegl, L., Thoma-Greber, E., Rocken, M. and Korting, HC. (1998) Persistent oral candidosis by non-albicans Candida strains including Candida glabrata in a human immunodeficiency virus-infected patient observed over a period of 6 years. Mycoses, 41, pp. 335-338.
16. Korting, HC, Schaller, M. Eder, G. et al. (1999) Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother, 43, pp. 2038-2042.
17. Cassone, A., De Bernardis, F. Torosantucci, A. et al. (1999) In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis, 180, pp. 448-453.
18. Nho, S., Anderson, MJ, Moore, CB and Denning, DW. (1997) Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. J Clin Microbiol, 35, pp. 1036-1039.
19. Chakrabarti, A., Ghosh, A. Batra, R. et al. (1996) Antifungal susceptibility pattern of non-albicans Candida species & distribution of species isolated from Candidaemia cases over a 5 year period. Indian J Med Res, 104, pp. 171-176.
20. Collin, B., Clancy, CJ and Nguyen, MH. (1999) Antifungal resistance in non- albicans Candida species. Drug Resist Updat, 2, pp. 9-14.
21. Fidel Jr, PL, Vazquez, JA and Sobel, JD. (1999) Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev, 12, pp. 80-96.
22. Colombo, AL, Perfect, J. DiNubile, M. et al. (2003) Global distribution and outcomes for Candida species causing invasive candidiasis: Results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis, 22, pp. 470-474.
23. Migliorati, CA, Birman, EG and Cury, AE. (2004) Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 98, pp. 301-310.
24. Tacconelli, E., Bertagnolio, S. Posteraro, B. et al. (2002) Azole susceptibility patterns and genetic relationship among oral Candida strains isolated in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr, 31, pp. 38-44.
25. Markowitz, M., Saag, M. Powderly, WG et al. (1995) A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med, 333, pp. 1534-1539.
26. De Bernardis, F., Boccanera, M. Rainaldi, L. et al. (1992) The secretion of aspartyl proteinase, a virulence enzyme, by isolates of Candida albicans from the oral cavity of HIV-infected subjects. Eur J Epidemiol, 8, pp. 362-367.
27. Abad-Zapatero, C., Goldman, R. Muchmore, SW et al. (1996) Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: Implications for the design of antifungal agents. Protein Sci, 5, pp. 640-652.
28. Bein, M., Schaller, M. and Korting, HC. (2002) The secreted aspartic proteinases as a new target in the therapy of candidiasis. Curr Drug Targets, 3, pp. 351-357.
29. Beighton, D., Ludford, R. Clark, DT et al. (1995) Use of CHROMagar Candida medium for isolation of yeasts from dental samples. J Clin Microbiol, 33, pp. 3025-3027.
30. Pindborg, JJ and Williams, DM. (1993) [An update of the classification and of the diagnostic criteria of oral lesions in HIV infection. The European Economic Community (EEC) and the Collaborative Center of the World Health Organization for the Oral Manifestations of HIV Infection]. Minerva Stomatol, 42, pp. 223-227.
31. Axell, T., Samaranayake, LP, Reichart, PA and Olsen, I. (1997) A proposal for reclassification of oral candidosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 84, pp. 111-112.
32. Ramos-Gomez, FJ, Petru, A. Hilton, JF et al. (2000) Oral manifestations and dental status in paediatric HIV infection. Int J Paediatr Dent, 10, pp. 3-11.
33. Sandven, P. (1990) Laboratory identification and sensitivity testing of yeast isolates. Acta Odontol Scand, 48, pp. 27-36.
34. Sano, A., Vilela, MMS Takahashi, I. et al. (2000) Isolation of Candida dubliniensis from the oral cavity of an HIV-positive child from Brazil. Jap J Med Mycol, 3, pp. 57-59.
35. Kievits, T., van Gemen, B. van Strijp, D. et al. (1991) NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods, 35, pp. 273-286.
36. Albert, J. and Fenyo, EM. (1990) Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers. J Clin Microbiol, 28, pp. 1560-1564.
37. National Committee for Clinical Laboratory Standard (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, NCCLS document M27-2A, Wayne, PA
38. Zaugg, C., Borg-Von Zepelin, M, Reichard, U., Sanglard, D. and Monod, M. (2001) Secreted aspartic proteinase family of Candida tropicalis. Infect Immun, 69, pp. 405-412.
39. Schoofs, AG, Odds, FC, Colebunders, R., Ieven, M. and Goossens, H. (1998) Cross-sectional study of oral Candida carriage in a human immunodeficiency virus (HIV)-seropositive population: Predisposing factors, epidemiology and antifungal susceptibility. Mycoses, 41, pp. 203-211.
40. Ceballos-Salobrena, A., Gaitan-Cepeda, LA, Ceballos-Garcia, L. and Lezama-Del Valle, D. (2000) Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: A new face of oral AIDS?. AIDS Patient Care STDS, 14, pp. 627-635.
41. Frezzini, C., Leao, JC and Porter, S. (2005) Current trends of HIV disease of the mouth. J Oral Pathol Med, 34, pp. 513-531.
42. Muller, FM, Groll, AH and Walsh, TJ. (1999) Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus. Eur J Pediatr, 158, pp. 187-199.
43. Muller, FM, Weig, M., Peter, J. and Walsh, TJ. (2000) Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother, 46, pp. 338-340.